Anatumomab mafenatox

Anatumomab mafenatox (ABR-214936) is a 73 KDa recombinant protein to recognize the tumor-associated antigen 5T4, which is widely expressing in malignancy. Anatumomab mafenatox is between a modified form of SEA and a murine Fab. The main side effects of Anatumomab mafenatox are reported to include fever, low blood pressure, pain, nausea and drowsiness[1].

Product Specifications

CAS Number

[1370261-50-9]

Product Name Alternative

ABR-214936

UNSPSC

12352203

Target

Transmembrane Glycoprotein

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/anatumomab-mafenatox.html

Solubility

10 mM in DMSO

Smiles

[Anatumomabmafenatox]

References & Citations

[1]Shaw DM, et al. A phase II study of a 5T4 oncofoetal antigen tumour-targeted superantigen (ABR-214936) therapy in patients with advanced renal cell carcinoma. Br J Cancer. 2007 Feb 26;96 (4) :567-74.